Vitamin B3 comprises niacin (nicotinic acid) and niacinamide (nicotinamide), water-soluble B vitamins that serve as obligate precursors to the coenzymes NAD+ (nicotinamide adenine dinucleotide) and NADP+ (nicotinamide adenine dinucleotide phosphate). These dinucleotides function as universal electron carriers in cellular metabolism, essential for glycolysis, the TCA cycle, electron transport, fatty acid synthesis, and antioxidant defense, while also serving as consumable substrates for DNA repair enzymes (PARP), longevity regulators (Sirtuins), and calcium signaling proteins (CD38).
Think of NAD+ as the rechargeable battery pack that powers your entire cellular factory. Every time a glucose molecule gets broken down for energy, the machinery needs to hand off hydrogen ions (H+) β the "exhaust" of metabolism β to something that can carry them away. NAD+ is the delivery truck that accepts these hydrogens (becoming NADH), drives them to the mitochondrial power plant, and delivers them to the Electron transport chain where they're converted into ATP. Without enough B3 to build these trucks, the factory floor gets clogged with hydrogen ions, metabolism stalls, and the lights start flickering.
But here's the twist: NAD+ isn't just a truck β it's also the fuel consumed by your cellular repair crew. Every time PARP enzymes fix broken DNA, they rip apart an NAD+ molecule to power the repair. Sirtuins β your longevity managers β do the same thing when they modify proteins to extend cellular lifespan. CD38, a calcium-signaling enzyme, also burns NAD+ like gasoline. So as you age, three problems converge: (1) you make less NAD+, (2) chronic inflammation activates PARP and CD38 (burning NAD+ faster), and (3) your mitochondria have fewer "trucks" available for energy production. The factory slows down, the repair crew runs out of supplies, and the whole operation ages prematurely.
graph TB
A[Niacin/Nicotinic Acid] --> B[Nicotinic Acid Mononucleotide]
B --> C["NAD+"]
D[Niacinamide/Nicotinamide] --> E[Nicotinamide Mononucleotide NMN]
E --> C
F[Tryptophan] --> G[Quinolinic Acid]
G --> B
C --> H["NADP+ via NAD kinase"]
C --> I["NAD+ Consumers"]
I --> J[Sirtuins - Protein Deacetylation]
I --> K[PARPs - DNA Repair]
I --> L["CD38 - CaΒ²βΊ Signaling"]
C --> M[NADH via Dehydrogenases]
M --> N[Electron Transport Chain]
De Novo Synthesis (Kynurenine Pathway):
Preiss-Handler Pathway (Salvage):
- Niacin (nicotinic acid) β nicotinic acid mononucleotide (via nicotinic acid phosphoribosyltransferase, NAPRT) β nicotinic acid adenine dinucleotide (via NMNAT) β NAD+ (via NAD synthetase, NADS)
Salvage Pathway (Primary Route):
- Niacinamide β nicotinamide mononucleotide (NMN, via nicotinamide phosphoribosyltransferase, NAMPT) β NAD+ (via NMNAT1/2/3)
- NAMPT is rate-limiting and declines with Aging
- CD38 increases with age, hydrolyzing NAD+ to nicotinamide and ADP-ribose (consuming up to 100-fold more NAD+ in aged tissues)
NAD+ as Electron Carrier:
- Glycolysis: Glyceraldehyde-3-phosphate dehydrogenase oxidizes G3P β 1,3-bisphosphoglycerate, reducing NAD+ β NADH
- TCA cycle: Isocitrate β Ξ±-ketoglutarate (isocitrate dehydrogenase), Ξ±-ketoglutarate β succinyl-CoA (Ξ±-ketoglutarate dehydrogenase), malate β oxaloacetate (malate dehydrogenase) β all reduce NAD+ β NADH
- Ξ²-oxidation: Acyl-CoA dehydrogenase and Ξ²-hydroxyacyl-CoA dehydrogenase produce NADH
- Electron transport chain: NADH delivers electrons to Complex I (NADH dehydrogenase) β ubiquinone β Complex III β cytochrome c β Complex IV β Oβ, pumping H+ to generate mitochondrial membrane potential for ATP production
NADP+ Functions:
- Generated from NAD+ via NAD kinase (adds phosphate group)
- Reduced to NADPH by glucose-6-phosphate dehydrogenase (pentose phosphate pathway), isocitrate dehydrogenase (cytosolic), and malic enzyme
- NADPH provides reducing power for:
- Fatty acid synthesis (fatty acid synthase)
- Cholesterol synthesis (HMG-CoA reductase pathway)
- Antioxidant defense: Glutathione reductase (GSSG β 2 GSH), thioredoxin reductase
- Detoxification: CYP450 enzymes, nitric oxide synthase
NAD+ Consumption:
- Sirtuins (SIRT1-7): NAD+-dependent protein deacetylases regulating metabolism, mitochondrial biogenesis, DNA repair, inflammation
- PARP enzymes (PARP1, PARP2): Consume NAD+ during DNA strand break repair, adding ADP-ribose polymers to nuclear proteins
- PARP1 hyperactivation (e.g., Oxidative Stress, genotoxic stress) can deplete NAD+ by >90% within minutes
- CD38: NADase and ADP-ribosyl cyclase, converts NAD+ β cyclic ADP-ribose (cADPR) and nicotinamide
- Increases dramatically with age and chronic inflammation
- Present on immune cells, adipocytes, vascular smooth muscle
- CD157: Similar NADase activity, expressed on leukocytes and bone marrow stromal cells
NAD+ availability is the master bottleneck for cellular energy production in cPNI. Patients with chronic fatigue syndrome, Fibromyalgia, Long COVID, post-viral syndromes, and metabolic syndrome often exhibit functional NAD+ depletion due to: (1) chronic low-grade inflammation activating CD38 and PARP, (2) mitochondrial dysfunction reducing NADH oxidation capacity, (3) age-related NAMPT decline, and (4) poor micronutrient status (B1, B2, B6 required as cofactors for NAD+-dependent enzymes).
Selfish Brain Context: When systemic NAD+ drops, the Selfish Brain prioritizes cerebral NAD+ allocation, potentially at the expense of peripheral tissues. This manifests as brain fog, cognitive dysfunction, and systemic metabolic slowdown β the brain pulls NAD+ precursors centrally, leaving muscles, liver, and immune cells undersupplied.
Metamodel Integration:
- Metamodel 0 (Evolutionary Mismatch): Modern diets high in processed foods and low in niacin-rich organ meats, seafood, and whole grains create subclinical B3 deficiency. Hunter-Gatherer diets provided 30-50 mg/day niacin equivalents; modern diets often <15 mg/day.
- Metamodel 1 (Lifestyle): Chronic stress, sleep deprivation, and sedentary behavior suppress NAMPT and increase NAD+ consumption via stress-activated PARP. Intermittent fasting and Exercise upregulate NAMPT and sirtuin activity.
- Metamodel 3 (Immune-Metabolic Interface): Inflammatory cytokines (IL-6, TNF-Ξ±) upregulate IDO, shunting Tryptophan to kynurenine pathway, reducing serotonin while increasing neurotoxic quinolinic acid and theoretically NAD+ synthesis β but net effect is often NAD+ depletion due to PARP/CD38 activation overwhelming synthesis.
ΒΆ NAD+ Decline and Aging
NAD+ tissue levels decline 50-80% between ages 30 and 80. This decline drives:
- Mitochondrial dysfunction (ATP production drops, ROS increases)
- Reduced sirtuin activity β impaired autophagy, mitochondrial biogenesis, metabolic flexibility
- Impaired DNA repair capacity β genomic instability
- Endothelial dysfunction β vascular aging
- Immune senescence β chronic inflammation (inflammaging)
Intervention Implications:
- Nicotinamide riboside (NR, 250-500 mg/day) and nicotinamide mononucleotide (NMN, 250-1000 mg/day) bypass NAMPT and raise NAD+ levels 30-60% in human trials
- Niacinamide (500-1000 mg/day) provides direct NAD+ substrate but may inhibit sirtuins at high doses (negative feedback on NAD+ consumption)
- High-dose niacin (1-3 g/day) lowers LDL by 15-20%, raises HDL by 20-35% via GPR109A (HCA2 receptor) activation, which reduces hepatic VLDL secretion and lipolysis. Side effect: prostaglandin Dβ-mediated flushing (blocked by aspirin or extended-release formulations).
- CD38 inhibitors (apigenin, quercetin) may preserve NAD+ by reducing degradation
- Support NAMPT expression: caloric restriction, resveratrol, Exercise, circadian rhythm optimization
ΒΆ Pellagra and Subclinical Deficiency
Classic Pellagra (4 Ds):
- Dermatitis (photosensitive rash, Casal's necklace)
- Diarrhea (mucosal inflammation, malabsorption)
- Dementia (neuropsychiatric symptoms, confusion, memory loss)
- Death (if untreated)
Caused by severe deficiency (<2 mg/day niacin equivalent), historically seen in populations dependent on untreated maize (niacin bound to indigestible complexes without nixtamalization). Rare in developed nations but seen in alcoholism, anorexia, malabsorption syndromes, carcinoid syndrome (tryptophan diverted to serotonin).
Subclinical Deficiency (<10 mg/day):
- Fatigue, irritability, poor concentration
- Impaired glucose tolerance (NAD+ required for insulin secretion and GLUT4 translocation)
- Reduced exercise capacity (impaired glycolysis and TCA cycle flux)
- Elevated homocysteine (NAD+ required for betaine-homocysteine methyltransferase, BHMT)
- No reliable direct NAD+ assay in routine labs (requires specialized LC-MS/MS)
- Indirect markers: elevated lactate-to-pyruvate ratio (impaired NADH oxidation), low NADH/NAD+ ratio in research settings
- Urinary N-methylnicotinamide <5.8 mg/day suggests deficiency
- Red blood cell NAD+ levels (research only) <40 Β΅M associated with mitochondrial dysfunction
- RDA: 16 mg niacin equivalents (NE) for men, 14 mg NE for women; 1 NE = 1 mg niacin or 60 mg Tryptophan
- Tissue NAD+ concentration: 200-500 Β΅M (young tissues), declines to 50-150 Β΅M by age 80
- NAD+/NADH ratio: Cytosol ~700:1, mitochondria ~7:1 (reduced state indicates metabolic stress)
- Tryptophan conversion inefficiency: Only 1.6% of dietary Tryptophan converts to niacin under optimal conditions; inflammatory states reduce this further via IDO upregulation
- PARP activation can deplete NAD+ by >90% within minutes during acute genotoxic stress (e.g., oxidative DNA damage, chemotherapy)
- CD38 expression increases 5-10 fold with aging and chronic inflammation, becoming the dominant NAD+ consumer in elderly tissues
- High-dose niacin (1-3 g/day): Lowers LDL 15-20%, raises HDL 20-35%, lowers triglycerides 20-50%; causes flushing in >80% of users (mediated by PGE2 and PGD2 via GPR109A activation on Langerhans cells and macrophages)
- Niacinamide does not cause flushing (does not activate GPR109A) but lacks lipid-modifying effects
- NAD+ supplementation (NR, NMN) increases NAD+ 30-60% in human trials at 250-1000 mg/day, with improved insulin sensitivity, mitochondrial function, and endurance in some studies
- NAMPT (rate-limiting enzyme) expression follows circadian rhythm, peaking in early morning (align supplementation timing for optimization)
- Pellagra threshold: <2 mg/day niacin equivalent for >60 days; subclinical symptoms <10 mg/day
- NAD β B3 is the obligate dietary precursor; NAD+ biosynthesis pathways converge on niacin or Tryptophan
- Electron transport chain β NADH delivers electrons to Complex I, driving proton gradient and ATP production
- TCA cycle β Isocitrate dehydrogenase, Ξ±-ketoglutarate dehydrogenase, and malate dehydrogenase all reduce NAD+ to NADH; rate-limited by NAD+ availability
- Sirtuins β NAD+-dependent deacetylases; SIRT1 regulates PGC-1alpha, FOXO, NF-ΞΊB; SIRT3 maintains mitochondrial function; activity declines with NAD+ depletion
- Mitochondria β NAD+/NADH ratio determines mitochondrial redox state; NAD+ required for Ξ²-oxidation, TCA cycle, and Complex I electron entry
- PARP β Poly(ADP-ribose) polymerase consumes NAD+ during DNA repair; hyperactivation during oxidative stress depletes cellular NAD+ and triggers cell death
- Tryptophan β Precursor to NAD+ via kynurenine pathway (60:1 conversion ratio); inflammatory upregulation of IDO diverts Tryptophan from Serotonin to kynurenine/NAD+
- Aging β NAD+ decline is a hallmark of aging (50-80% drop), driving mitochondrial dysfunction, reduced sirtuin activity, impaired DNA repair, and immune senescence
- Vitamin B1 β Thiamine pyrophosphate (TPP) is cofactor for Ξ±-ketoglutarate dehydrogenase and pyruvate dehydrogenase, which produce NADH; B1 deficiency impairs NAD+ utilization
- Vitamin B2 β Riboflavin forms FAD, which accepts electrons from NADH via Complex I (NADH-ubiquinone oxidoreductase); B2 deficiency impairs NADH oxidation
- Folate β 5-MTHF required for Homocysteine remethylation; NAD+ required for BHMT (alternative pathway); dual deficiency elevates homocysteine
- Coenzyme Q10 β Accepts electrons from NADH (via Complex I) and FADHβ (via Complex II) in electron transport chain; CoQ10 deficiency impairs NADH oxidation
- Chronic inflammation β IL-6, TNF-Ξ± upregulate CD38 and activate PARP, accelerating NAD+ consumption; IDO activation diverts Tryptophan
- Insulin resistance β NAD+ depletion impairs GLUT4 translocation and glucose oxidation; NAD+ repletion improves insulin sensitivity via SIRT1-mediated pathways
- Metabolic syndrome β Low NAD+ drives mitochondrial dysfunction, impaired fatty acid oxidation, hepatic steatosis, and reduced energy expenditure
- Chronic fatigue syndrome β NAD+ depletion hypothesis supported by impaired mitochondrial function, oxidative stress, and PARP activation in CFS patients
- Exercise β Upregulates NAMPT expression, increases NAD+ biosynthesis, activates SIRT1/PGC-1Ξ± axis for mitochondrial biogenesis and metabolic adaptation
- Caloric restriction β Increases NAD+/NADH ratio, activates sirtuins, extends lifespan in model organisms; mimicked by NAD+ precursor supplementation
- Omega-3 β DHA and EPA reduce inflammation, potentially sparing NAD+ by reducing PARP/CD38 activation and IDO upregulation
- Glucose metabolism β NAD+ required for glyceraldehyde-3-phosphate dehydrogenase (glycolysis step 6); NAD+ depletion blocks glucose oxidation, forcing anaerobic glycolysis
- Oxidative Stress β Activates PARP1, massively consuming NAD+ during DNA repair; chronic oxidative stress depletes NAD+ pool and impairs energy metabolism